kentucky glp-1 stomach paralysis law firm nausea legal team intestinal attorney kentucky glp -1 GLP-1s aren't glp-1 intestinal paralysis office – As GLP -1 drugs continue to – kentucky semaglutide gi obstruction law

Science, 293(5532), 1068-1070

Cardiovascular Outcomes# EXSCEL Trial (Exenatide)# The EXSCEL trial (Holman et al., NEJM 2017) enrolled 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease) and followed them for a median of 3.2 years: Primary MACE endpoint : HR 0.91 (95% CI 0.83-1.00), p=0.06 for superiority Met non-inferiority but narrowly missed superiority (p=0.06) All-cause mortality was reduced by 14% (HR 0.86, p=0.016) in a secondary analysis EXSCEL confirmed cardiovascular safety but did not prove cardiovascular benefit -- a critical distinction

For researchers serious about understanding their GLP-1 protocols fully, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, detailed safety profiles, calculators for accurate dosing, and a community of thousands who have navigated these exact questions

10.3389/fneur.2020.594672 Front